Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > REGULATORY
REGULATORY
- LDP Eyes Filing of 15 Sakigake Designated Products by FY2018
June 9, 2015
- Kaketsuken Suspends Shipments of 12 Products Due to Modifications of Approved Manufacturing Procedures
June 9, 2015
- Editor’s Pick: Five Healthcare News Headlines for May 25 - June 7
June 8, 2015
- MHLW’s Jo Urges Generic Makers to Formulate Careful Investment Plans
June 8, 2015
- Govt Working Group Suspicious about Supply Limitation Hindering Generic Goal
June 8, 2015
- PAFSC 1st Committee Backs Approval of Lilly’s GLP-1 Receptor Agonist Dulaglutide
June 8, 2015
- 8 Members of PAFSC’s Pharmaceutical Affairs Council to Be Ousted for Violating COI Rules
June 8, 2015
- Roughly 60 Products Submitted as Candidates for Review under Sakigake Designation System
June 8, 2015
- LDP Study Group Agrees on Good Balance between Generic Promotion, Innovation
June 5, 2015
- Prime Minister Abe Asks Health Minister to Formulate New Measures against Cancer by Year-End
June 4, 2015
- MHLW to Launch Switch OTC Panel as Early as Summer
June 3, 2015
- MHLW Calls for Revision of Package Insert for Xalkori
June 3, 2015
- MHLW Stands by “80% in FY2020” as New Generic Use Target, Says It’s “Barely Reachable”
June 2, 2015
- MOF Panel Recommends Generic Target of 80% by FY2017-End
June 2, 2015
- JPMA Says Generic Target Has Huge Impact on Innovation, Balanced Approach Needed
June 1, 2015
- Lawmakers Tepid on Health Issues amid Weak Lobbying Campaigns on Generics, Drug Price Cuts
June 1, 2015
- AMED Hopes to Create Fund to Nurture Researchers through Contributions from Drug Makers: President Suematsu
June 1, 2015
- MHLW’s Ryukaikon Council to Meet on June 17 to Review Distribution Conditions in FY2014
June 1, 2015
- 12 APIs/15 Products including Lantus Biosimilars Added to NHI Price List
May 29, 2015
- Gilead’s Combination Hep C Drug Likely to Win Japan Approval Late June
May 29, 2015
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…